ClinicalTrials.gg
CompletedNCT00069836Updated Sep 1, 2016

Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.

A Phase 3 interventional study of Rosiglitazone/metformin in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 93 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-09-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.

Enrollment
18th of 51
272 · median 149
Started
2003
with 5 others
Phase 3
21 of 52
none open now
Registered
4th of 52
by date
Lead sponsor
22 of 52
GlaxoSmithKline

Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2003, is one of 21 in phase 3, and was the 4th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rosiglitazone

Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This study was designed to test the safety and efficacy (how well it works) of AVANDAMET in combination with insulin in improving the control of blood sugar when compared with taking insulin on its own. AVANDAMET capsules contain a fixed dose of AVANDIA and metformin. Both AVANDIA and metformin are medicines which are individually licensed for the treatment of type II diabetes mellitus. Because they act in different ways, it is thought that combining them may give an increased benefit of treating diabetes and reducing blood sugar.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • AVANDAMET insulin type 2 diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have been diagnosed with type II diabetes mellitus and not have adequate glycaemic controlled while receiving at least 1.5g of metformin.
  • Patients must have a of greater than 25 kg/m2 and must not suffer from ankle swelling.

Exclusion criteria

Exclusion Criteria:

  • Patients cannot have any form of congestive heart failure or severe or unstable angina.
  • Patients cannot be currently receiving insulin, but be prepared to begin insulin treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
272 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Rosiglitazone/metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c

    Time frame: 24 weeks

Secondary outcomes

  1. Insulin dose, FPG,glycaemic responders, beta-cell function, hypoglycaemia, treatment satisfaction

    Time frame: 24 weeks

07

Study locations

93 sites
  • GSK Investigational Site
    Vienna, A-1030, Austria
  • GSK Investigational Site
    Vienna, A-1060, Austria
  • GSK Investigational Site
    Roubaix, Nord-Pas-de-Calais 59100, France
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Bondy Cedex, 93143, France
  • GSK Investigational Site
    Cholet, 49300, France
  • GSK Investigational Site
    Corbeil Essonnes Cedex, 91106, France
  • GSK Investigational Site
    Douai Cedex, 59507, France
  • GSK Investigational Site
    Epinay sur Orge, 91360, France
  • GSK Investigational Site
    La Rochelle Cedex 1, 17019, France
  • GSK Investigational Site
    Lorient, 56322, France
  • GSK Investigational Site
    Lyon Cedex 03, 69394, France
  • GSK Investigational Site
    Montbrison, 42600, France
  • GSK Investigational Site
    Nantes Cedex 1, 44093, France
  • GSK Investigational Site
    Paris, 75015, France
  • GSK Investigational Site
    Pierre Benite Cedex, 69495, France
  • GSK Investigational Site
    Reims Cedex, 51092, France
  • GSK Investigational Site
    Rennes Cedex 2, 35203, France
  • GSK Investigational Site
    Saint Malo Cedex, 35403, France
  • GSK Investigational Site
    Toul Cedex, 54201, France
  • GSK Investigational Site
    Venissieux, 69200, France
  • GSK Investigational Site
    Hermaringen, Baden-Wuerttemberg 89568, Germany
  • GSK Investigational Site
    Kippenheim, Baden-Wuerttemberg 77971, Germany
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68161, Germany
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68199, Germany
  • GSK Investigational Site
    Sinsheim, Baden-Wuerttemberg 74889, Germany
  • GSK Investigational Site
    Stockach, Baden-Wuerttemberg 78333, Germany
  • GSK Investigational Site
    Ilvesheim, Bayern 68549, Germany
  • GSK Investigational Site
    Kuenzing, Bayern 94550, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80469, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81373, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81549, Germany
  • GSK Investigational Site
    Wallerfing, Bayern 94574, Germany
  • GSK Investigational Site
    Falkensee, Brandenburg 14612, Germany
  • GSK Investigational Site
    Potsdam, Brandenburg 14467, Germany
  • GSK Investigational Site
    Schwedt, Brandenburg 16303, Germany
  • GSK Investigational Site
    Bad Kreuznach, Hessen 55545, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60326, Germany
  • GSK Investigational Site
    Schluechtern, Hessen 36381, Germany
  • GSK Investigational Site
    Vellmar, Hessen 34246, Germany
  • GSK Investigational Site
    Hildesheim, Niedersachsen 31139, Germany
  • GSK Investigational Site
    Aachen, Nordrhein-Westfalen 52070, Germany
  • GSK Investigational Site
    Bad Oeynhausen, Nordrhein-Westfalen 32549, Germany
  • GSK Investigational Site
    Beckum, Nordrhein-Westfalen 59269, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44137, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 51065, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 51069, Germany
  • GSK Investigational Site
    Neuss, Nordrhein-Westfalen 41466, Germany
  • GSK Investigational Site
    Viersen, Nordrhein-Westfalen 41751, Germany
  • GSK Investigational Site
    Altenkirchen, Rheinland-Pfalz 57610, Germany
  • GSK Investigational Site
    Ludwigshafen, Rheinland-Pfalz 67061, Germany
  • GSK Investigational Site
    Rhaunen, Rheinland-Pfalz 55624, Germany
  • GSK Investigational Site
    Simmern, Rheinland-Pfalz 55469, Germany
  • GSK Investigational Site
    Speyer, Rheinland-Pfalz 67346, Germany
  • GSK Investigational Site
    Saarlouis, Saarland 66740, Germany
  • GSK Investigational Site
    Halberstadt, Sachsen-Anhalt 38820, Germany
  • GSK Investigational Site
    Halle, Sachsen-Anhalt 06112, Germany
  • GSK Investigational Site
    Halle, Sachsen-Anhalt 06114, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01219, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Freital, Sachsen 01705, Germany
  • GSK Investigational Site
    Pirna, Sachsen 01796, Germany
  • GSK Investigational Site
    Gotha, Thueringen 99867, Germany
  • GSK Investigational Site
    Schleiz, Thueringen 07907, Germany
  • GSK Investigational Site
    Berlin, 10789, Germany
  • GSK Investigational Site
    Berlin, 12347, Germany
  • GSK Investigational Site
    Berlin, 12351, Germany
  • GSK Investigational Site
    Berlin, 13057, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Hamburg, 22041, Germany
  • GSK Investigational Site
    Hamburg, 22607, Germany
  • GSK Investigational Site
    Parma, Emilia-Romagna 43100, Italy
  • GSK Investigational Site
    Pordenone, Friuli-Venezia-Giulia 33170, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Perugia, Umbria 06126, Italy
  • GSK Investigational Site
    Padova, Veneto 35128, Italy
  • GSK Investigational Site
    Treviso, Veneto 31100, Italy
  • GSK Investigational Site
    Alcobendas/Madrid, 28100, Spain
  • GSK Investigational Site
    Alicante, Spain
  • GSK Investigational Site
    Barcelona, 08022, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Cadiz, 11009, Spain
  • GSK Investigational Site
    Galdakano, 48960, Spain
  • GSK Investigational Site
    Granada, 18012, Spain
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Móstoles/Madrid, 28935, Spain
  • GSK Investigational Site
    Pontevedra, 36002, Spain
  • GSK Investigational Site
    Sabadell (Barcelona), 08208, Spain
  • GSK Investigational Site
    San Juan De Alicante, 3550, Spain
  • GSK Investigational Site
    Valencia, 46010, Spain
  • GSK Investigational Site
    Vigo/Pontevedra, 36200, Spain
08

References and documents

Publications

  • Home PD, Bailey CJ, Donaldson J, Chen H, Stewart MW. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes. Diabet Med. 2007 Jun;24(6):618-25. doi: 10.1111/j.1464-5491.2007.02141.x. Epub 2007 Apr 2. Erratum In: Diabet Med. 2010 May;27(5):611. PubMed 17403121 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Nov 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2003
First posted
Oct 3, 2003
Start
Oct 2003
Primary completionActual
Nov 2004
CompletionActual
Nov 2004
Last update
Sep 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00069836
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 3, 2003
Start date
Oct 2003
Primary completion
Nov 2004
Completion
Nov 2004
Last update
Sep 1, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosiglitazone · Metformin

Start the discussion